Bloomberg -- Exelixis Inc. (EXEL) is working with Goldman Sachs Group Inc. (GS) to prepare for potential takeover offers after its experimental drug helped prostate-cancer patients in a study, said people with knowledge of the matter.
Bloomberg -- Exelixis Inc. (EXEL) is working with Goldman Sachs Group Inc. (GS) to prepare for potential takeover offers after its experimental drug helped prostate-cancer patients in a study, said people with knowledge of the matter.
